This study investigates the effects of gut hormones, specifically GLP-1 and DPP-4 inhibition, on food intake and glucose metabolism post-Roux-en-Y gastric bypass (RYGB). Given the rising prevalence of obesity and related metabolic disorders, successful outcomes could enhance the commercial viability of GLP-1 receptor antagonists and DPP-4 inhibitors in obesity management. The competitive landscape includes established players like Merck (sitagliptin) and Novo Nordisk (liraglutide), necessitating a thorough diligence process to assess market entry strategies and potential partnerships. The findings may also inform future product development and positioning in the obesity treatment market.